I am different, not less.
Dr. Temple Grandin
Professor of Animal Husbandry, Colorado State University

Genetics, Brain Connections and Autism

Autism Spectrum Disorder (ASD) is a common condition that impacts many individuals, yet effective treatment options remain limited despite decades of research. Often, treatments provide only partial relief from symptoms, leaving families searching for better solutions. This is where photobiomodulation (PBM) steps in as an innovative and promising approach.

Why PBM for ASD?
One of the most exciting developments in ASD treatment is transcranial photobiomodulation (t-PBM). Unlike medications or invasive procedures, t-PBM is a non-invasive brain modulation technique that uses light at specific wavelengths to target brain activity. For individuals with ASD, early studies have shown that PBM with near-infrared radiation (NIR) can produce meaningful improvements in various symptoms.

How does it work?
PBM works by improving mitochondrial function in the brain, boosting ATP production (the brain’s energy source), and enhancing blood flow. This allows the brain to operate more efficiently, with better connectivity between critical regions involved in social behavior, communication, and emotional regulation.

What are the benefits?
The potential benefits of PBM for individuals with ASD are wide-ranging:

  • Improved Social Interaction and Communication: PBM stimulates brain areas like the dorsomedial prefrontal cortex (dmPFC) and temporoparietal junction (TPJ), enhancing the ability to interpret social cues and communicate more effectively.
  • Reduction in Repetitive Behaviors: By modulating neural circuits, PBM can help reduce repetitive behaviors often seen in ASD.
  • Enhanced Cognitive Function: Increased ATP production supports better focus, memory, and overall mental clarity.
  • Calmer Mood and Reduced Anxiety: PBM helps regulate neurotransmitters like serotonin and GABA, promoting relaxation and reducing stress.
  • Better Sensory Processing: It can balance brain activity in sensory regions, reducing sensory overload and improving response to stimuli.
  • Improved Sleep Patterns: Many with ASD struggle with sleep issues. PBM can regulate melatonin production and circadian rhythms, leading to better sleep.
  • Reduction in Neuroinflammation: Inflammation in the brain is a common issue in ASD, and PBM’s anti-inflammatory effects can alleviate this, improving overall brain function.
  • Increased Emotional Regulation: Targeting areas like the prefrontal cortex can help individuals manage emotions and reduce mood swings or meltdowns.

A New Era of Treatment
What makes PBM even more exciting is its safety and flexibility. It’s painless, drug-free, and has virtually no side effects, making it suitable for individuals of all ages. It can also be tailored to each person’s unique needs by adjusting the wavelength, intensity, and frequency of treatment.

As research continues to uncover the full potential of photobiomodulation, it’s clear that this groundbreaking therapy offers hope for a brighter future. Families and individuals with ASD may finally have a non-invasive, effective option to improve their quality of life and unlock their potential.

If you or someone you know is living with ASD, photobiomodulation might be worth exploring.

Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study

Stefano Pallanti, Michele Di Ponzio , Eleonora Grassi, Gloria Vannini and Gilla Cauli

Published in Children 2022, 9, 755

Summary:
Children with Autism Spectrum Disorder (ASD) face various challenges due to deficits in social functioning and communication, along with restricted behavioral patterns. They often exhibit difficult-to-manage and disruptive behavior. Currently, there are no pharmacological treatments for the core features of ASD. Recently, there has been growing interest in non-pharmacological interventions for ASD, such as neuromodulation.

This retrospective study reports and analyzes data from 21 patients (13 male, 8 female) with ASD, with a mean age of 9.1 years (range 5–15), who underwent six months of at-home transcranial photobiomodulation (tPBM) using two protocols (alpha and gamma), designed to modulate the alpha and gamma bands, respectively.

The patients were evaluated at baseline, after three months, and after six months of treatment using the Childhood Autism Rating Scale (CARS), the Home Situation Questionnaire-ASD (HSQ-ASD), the Autism Parenting Stress Index (APSI), the Montefiore Einstein Rigidity Scale–Revised (MERS-R), the Pittsburgh Sleep Quality Index (PSQI), and the SDAG to assess attention.

Findings indicate that tPBM was associated with a reduction in ASD severity, evidenced by a decrease in CARS scores during the intervention (p < 0.001). A significant reduction in non-compliant behavior and parental stress was also observed.

Additionally, improvements were reported in behavioral and cognitive rigidity, attention functions, and sleep quality.

Could Photobiomodulation Treat Autism Spectrum Disorder?

Michael R. Hamblin

Published in Photobiomodulation, Photomedicine, and Laser Surgery. Jun 2022. p367-369.

Autism Spectrum Disorder (ASD): An Overview and the Potential of Photobiomodulation (PBM)

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition typically diagnosed within the first three years of life. It affects boys four to five times more often than girls. Initially described in children by Leo Kanner in 1943 and further characterized by Hans Asperger in 1944 as “autistic psychopathy,” the broader classification of ASD is now widely recognized.

Key Features of ASD

ASD is characterized by four broad groups of symptoms:

  1. Core social communication skills
  2. Quality of interaction
  3. Interaction with peers and behavioral changes
  4. Social initiation and connection

The severity of symptoms varies widely, from nonverbal individuals with intellectual disabilities and repetitive behaviors to high-functioning individuals who may appear eccentric or socially unusual. Globally, ASD affects an estimated 24.8 million people, with an additional 37.2 million individuals impacted by Asperger’s syndrome.

Causes of ASD

The causes of ASD are multifactorial:

  • Genetic Basis: Siblings of children with ASD are 25 times more likely to be diagnosed, although only a few Mendelian mutations have been identified. Epigenetic factors likely play a significant role.
  • Environmental Factors: Maternal exposure to infections, toxins, poor nutrition, or inflammation during pregnancy may increase the risk.
  • Neurological Mechanisms: Evidence suggests that mitochondrial dysfunction, impaired synaptic development, neuroplasticity issues, disrupted neurogenesis, and excessive neuroinflammation contribute to ASD.

Conventional Treatments

Current ASD treatments focus on managing behavioral issues and improving quality of life and independence. These include:

  • Educational approaches like Applied Behavioral Analysis (ABA)
  • Speech, social skills, and occupational therapies
  • Cognitive Behavioral Therapy (CBT)
  • Medication for associated symptoms, such as stimulants, antidepressants, or antipsychotics.

The Role of Photobiomodulation (PBM) in ASD

PBM involves delivering red and near-infrared light to targeted areas of the body using lasers or LEDs. It is non-invasive, drug-free, and well-tolerated, with few side effects. PBM is already widely used for pain reduction, inflammation control, and wound healing.

Applications for Neurological Conditions

Transcranial photobiomodulation (tPBM) has shown promise in treating various brain disorders, including:

  • Traumatic brain injury
  • Stroke
  • Parkinson’s disease
  • Alzheimer’s disease
  • Psychiatric disorders

PBM devices, typically helmets or headsets equipped with LEDs, are used daily or semi-daily for 15-30 minutes over several weeks.

Mechanisms Relevant to ASD

Studies suggest PBM could benefit the underlying mechanisms of ASD by:

  • Enhancing mitochondrial function, improving ATP production, cerebral oxygenation, and cytochrome-c oxidase activity.
  • Promoting synaptogenesis and neurogenesis, as demonstrated in animal models.
  • Reducing neuroinflammation and microglial activation.

Clinical Evidence

Several studies have demonstrated the effectiveness of PBM in ASD:

  1. A 2018 study using a 640 nm low-level laser in children aged 5–17 showed significant reductions in irritability (p < 0.0001) compared to placebo.

  2. A pilot study at Massachusetts General Hospital applied 830 nm LED arrays to adults with ASD twice weekly for eight weeks. Participants showed significant improvements in:

    • Social awareness, communication, and motivation
    • Restricted/repetitive behaviors
    • Functioning and life satisfaction (p < 0.001) Side effects were mild and temporary, including insomnia and mild headaches.

  3. Clinical Trials with Children: A study involving 30 children (aged 2–6) using an 850 nm LED headband (15 minutes, twice weekly for eight weeks) reported significant improvements in the Childhood Autism Rating Scale (p = 0.02).

These promising results have led to a breakthrough device designation by the FDA and suggest tPBM could complement educational and psychotherapeutic approaches by enhancing synaptogenesis and neuroplasticity.

Looking Forward

The success of PBM in both preclinical and clinical studies highlights its potential as a non-pharmacological treatment for ASD. Ongoing and future clinical trials are expected to solidify its role in managing this complex condition and improving outcomes for individuals with ASD.

Transcranial Photobiomodulation in Adults with High-Functioning Autism Spectrum Disorder: Positive Findings from a Proof-of-Concept Study

Tolga Atilla Ceranoglu, Paolo Cassano, Barbora Hoskova, Allison Green, Nina Dallenbach, Maura DiSalvo, Joseph Biederman and Gagan Joshi

Published in Photobiomodulation, Photomedicine, and Laser Surgery. Jan 2022. p4-12

Objective:
To evaluate the efficacy and safety of transcranial photobiomodulation (tPBM) in adults with Autism Spectrum Disorder (ASD).

Methods:
High-functioning adults with ASD, aged 18 to 59 years, were enrolled in an open-label, single-group study to receive tPBM twice weekly for 8 weeks. ASD symptom severity was assessed at baseline, midpoint, and endpoint using clinician-rated, self-reported, and informant-assessed measures. Treatment response was defined as a 30% reduction in the Social Responsiveness Scale-2nd Edition (SRS-2) total score and an ASD Clinical Global Impression-Improvement score ≤2. Adverse events were recorded at each visit. Paired-samples t-test analyses were conducted.

Results:
Eleven participants were enrolled; 10 participants (9 males; 30.0 ± 11.9 years) completed the study, while one withdrew consent before baseline. All 10 completers were included in the efficacy and safety analyses. Five participants (50%) met the response criteria at the endpoint.

Overall, 8 weeks of tPBM was associated with a significant reduction in SRS-2 total scores at the endpoint (SRS-2: −30.6 ± 23, p < 0.001), particularly in:

  • Social Awareness: −3.0 ± 1.9, p < 0.001
  • Social Communication: −10.3 ± 6, p < 0.001
  • Social Motivation: −5.0 ± 2.4, p < 0.001
  • Restricted/Repetitive Behaviors: −7.4 ± 4.1, p < 0.001

There were statistically significant improvements at the endpoint in:

  • Global Assessment of Functioning scores: +12.8 ± 4.2, p < 0.001
  • Quality of Life Questionnaire (Pleasure and Satisfaction scores): +6.0 ± 7.9, p = 0.02

Three participants experienced transient, mild side effects (insomnia, headache, and warmth at the treatment site), but no adverse events required changes to the tPBM protocol. Treatment adherence was 98%.

Conclusions:
tPBM is a safe and feasible treatment approach with the potential to address core features of ASD.

The Story of Ozil

By Raymond Schoeman

I had the privilege of meeting Ozil and being a part of his life story, even if only for a short time. When we first met in July 2022, Ozil was 5 years old.

During our initial meeting, I couldn’t understand anything Ozil was trying to say. It wasn’t just the words—his sounds were unclear and hard to decipher.

We immediately started transcranial photobiomodulation therapy. His sessions included 30 minutes with the light helmet, followed by an additional 10 minutes—5 minutes on each side of his head—with a red and infrared combination device.

The sessions were spaced a week apart, with one session per week.

At the beginning of the second session, I asked his caregiver if she had noticed any changes over the past week. She mentioned that he was more understandable. It was hard to define at that stage, but definitely noticeable to those who interacted with him regularly.

One of the tracking tests we used was asking him to draw a spiral. Below, you can see the progression in the complexity of his spiral drawings.

Over the eight weeks (nine treatments) I worked with Ozil, his ability to talk and engage with others transformed dramatically. Within a month, he was speaking clearly. The most remarkable part was that he suddenly began using vocabulary no one knew he had.

His interactions with other people improved significantly, making his behavior much more pleasant. By the end of the eight weeks, I could have a basic conversation with Ozil and understand him clearly.

Below, you’ll find feedback from one of his primary caregivers during week seven of his treatments.

The Spirals of Ozil